![]() |
市場調查報告書
商品編碼
1377950
移植HLA型檢測市場:依產品與服務、技術、移植類型、應用、最終用戶 - 2023-2030 年全球預測HLA Typing for Transplant Market by Product & Service, Technology, Transplant Type, Application, End-User - Global Forecast 2023-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
可移植HLA型檢測市場預計將從2022年的9.19億美元增至2030年的18.3658億美元,預測期內年複合成長率為9.04%。
用於移植的HLA型檢測的全球市場
主要市場統計 | |
---|---|
基準年[2022] | 9.19億美元 |
預測年份 [2023] | 99831萬美元 |
預測年份 [2030] | 1,836.58 百萬美元 |
年複合成長率(%) | 9.04% |
FPNV定位矩陣是評估可移植HLA型檢測市場的必備工具。透過分析與業務策略和產品滿意度相關的關鍵指標來全面評估供應商。這使得使用者能夠根據自己的具體資訊做出明智的決策。進階分析將供應商分為四個像限,每個象限都有不同程度的成功:前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。這個富有洞察力的框架使決策者能夠充滿信心地駕馭市場。
市場佔有率分析為供應商的市場形勢提供了寶貴的見解。評估對整體收益、客戶群和其他關鍵指標的影響可以全面了解公司的業績及其面臨的競爭環境。該分析還揭示了研究期間的競爭水平,例如市場佔有率成長、碎片化、主導地位和行業整合。
1.市場滲透:提供有關市場動態和主要企業產品的全面資訊。
2. 市場開拓:詳細分析新興和成熟細分市場的滲透情況,以突顯利潤豐厚的商機。
3. 市場多元化:有關新產品發布、開拓地區、最新發展和投資的詳細資訊。
4.競爭評估與資訊:對主要企業的市場佔有率、策略、產品、認證、法規狀況、專利狀況、製造能力等進行綜合評估。
5. 產品開發與創新:對未來技術、研發活動和突破性產品開發的智慧洞察。
1.移植用HLA型檢測市場的市場規模與預測是多少?
2. 移植HLA型檢測市場中哪些產品、細分市場、應用和領域具有最高的投資潛力?
3.移植HLA型檢測市場的競爭策略窗口有哪些?
4.移植HLA型檢測市場的最新技術趨勢與法律規範是什麼?
5.移植HLA型檢測市場主要廠商的市場佔有率是多少?
6. 進入移植HLA型檢測市場的合適型態與策略手段是什麼?
The HLA Typing for Transplant Market is projected to reach USD 1,836.58 million by 2030 from USD 919.00 million in 2022, at a CAGR of 9.04% during the forecast period.
Global HLA Typing for Transplant Market
KEY MARKET STATISTICS | |
---|---|
Base Year [2022] | USD 919.00 million |
Estimated Year [2023] | USD 998.31 million |
Forecast Year [2030] | USD 1,836.58 million |
CAGR (%) | 9.04% |
This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the HLA Typing for Transplant Market.
Based on Product & Service, market is studied across Instruments, Reagents & Consumables, and Software & Services. The Reagents & Consumables commanded largest market share of 51.23% in 2022, followed by Instruments.
Based on Technology, market is studied across Molecular Assay Technologies and Non-Molecular Assay Technologies. The Molecular Assay Technologies is further studied across PCR-Based Molecular Assays and Sequencing-Based Molecular Assays. The PCR-Based Molecular Assays is further studied across Real-Time PCR, Sequence-Specific Oligonucleotide-PCR, and Sequence-Specific Primer-PCR. The Sequencing-Based Molecular Assays is further studied across Next-Generation Sequencing and Sanger Sequencing. The Molecular Assay Technologies commanded largest market share of 57.88% in 2022, followed by Non-Molecular Assay Technologies.
Based on Transplant Type, market is studied across Organ Transplantation, Stem Cell Transplantation, and Tissue Transplantation. The Tissue Transplantation commanded largest market share of 36.12% in 2022, followed by Organ Transplantation.
Based on Application, market is studied across Diagnostic Applications and Research Applications. The Diagnostic Applications is further studied across Antibody Screening and Chimerism Monitoring. The Research Applications commanded largest market share of 63.23% in 2022, followed by Diagnostic Applications.
Based on End-User, market is studied across Clinical Laboratories & Research Institution, Hospitals & Transplant Centers, and Independent Reference Laboratories. The Independent Reference Laboratories commanded largest market share of 52.12% in 2022, followed by Clinical Laboratories & Research Institution.
Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa commanded largest market share of 39.37% in 2022, followed by Americas.
The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.
The FPNV Positioning Matrix is an indispensable tool for assessing the HLA Typing for Transplant Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.
The Market Share Analysis offers invaluable insights into the vendor landscape HLA Typing for Transplant Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.
The report delves into recent significant developments in the HLA Typing for Transplant Market, highlighting leading vendors and their innovative profiles. These include Agilent Technologies, Inc., BAG Diagnostics GmbH, Becton, Dickinson, and Company, BGI Genomics Co.,Ltd., Bio-Rad Laboratories, Inc., Bio-Techne Corporation, CapitalBio Technology Co., Ltd., CareDx, Inc., CeGaT GmbH, Chugai Pharmaceutical Co., Ltd., Creative Biolabs, Inc., DiaSorin S.p.A., Eurofins Scientific SE, F. Hoffman-La Roche AG, Fujirebio, Inc. by H.U. Group Holdings, Inc., Garuda Therapeutics, GenDx by Eurobio Scientific Group, HEALIOS K.K., Hologic, Inc., Illumina, Inc., Immatics N.V., Immucor, Inc. by Werfen, S.A., ImmunOs Therapeutics AG, Invectys Inc., Laboratory Corporation of America Holdings, Lonza Group Ltd., Merck KGaA, NeoGenomics Laboratories, Inc., OraSure Technologies, Inc., Oxford Nanopore Technologies PLC, Pure MHC, LLC, Pure Protein, LLC, QIAGEN N.V., STEMCELL Technologies Inc., T-Cure Bioscience Inc., Takara Bio Inc., TBG Diagnostics Ltd., TCR² Therapeutics by Adaptimmune Therapeutics PLC, and Thermo Fisher Scientific, Inc..
1. Market Penetration: It provides comprehensive information about key players' market dynamics and offerings.
2. Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.
3. Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.
4. Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.
5. Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast for the HLA Typing for Transplant Market?
2. Which products, segments, applications, and areas hold the highest investment potential in the HLA Typing for Transplant Market?
3. What is the competitive strategic window for identifying opportunities in the HLA Typing for Transplant Market?
4. What are the latest technology trends and regulatory frameworks in the HLA Typing for Transplant Market?
5. What is the market share of the leading vendors in the HLA Typing for Transplant Market?
6. Which modes and strategic moves are suitable for entering the HLA Typing for Transplant Market?
TABL